Complete Remission in All 12 Colorectal Phase 2 Cancer Trial Patients

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time…
Complete Remission in All 12 Colorectal Phase 2 Cancer Trial Patients


A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

They used lab-made antibody called dostarlimab. It inhibits a protein known as programmed death receptor-1 (PD-1) found in many cancer cells. This inhibition then allows the immune system to recognize the cancer cells as harmful and target them for destruction. The drug was developed by GlaxoSmithKline, and it was given an accelerated approval by the Food and Drug Administration last year for cases of endometrial cancer linked to a mismatch repair deficiency.

The treatment exposes the cancer to the immune system.

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response.

The study involved researchers at the Memorial Sloan Kettering Cancer Center as well as Yale University, and it was sponsored by the pharmaceutical company GlaxoSmithKline.

The volunteers were all diagnosed with stage II or III rectal cancer, meaning their tumors had begun to grow larger and spread to nearby parts of the body.

New England Journal of Medicine – PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
Future Shock: Actual Objects
Read More

Future Shock: Actual Objects

Actual Objects on their immersive installation Vicky, which tells the story of a future disaster through multiple viewpoints. Actual Objects is an experimental creative studio whose practice focuses on world-building through a number of traditional and technological artistic techniques. Painting and live action film co-exist with 3D animation, AI and programming in the studio’s work, which…
Laser PB11 Fusion Yield Increased 40 Fold
Read More

Laser PB11 Fusion Yield Increased 40 Fold

There are three main types of nuclear fusion and PB11 (hydrogen-boron) is the most desired. PB11 nuclear fusion would have almost no neutron radiation but it takes 1 billion degree temperatures instead of 100 million for deuterium tritium or about 500 million for deuteriurm-deuterium. The PALS laser facility in Prague has reported a major advance…
8500 US and 40,000 NATO Troops Placed on Standby
Read More

8500 US and 40,000 NATO Troops Placed on Standby

The Pentagon has put 8500 troops on alert for possible deployment to Eastern Europe in case Russia invades the Ukraine. I think there is no chance of any direct US or NATO engagement of Russian troops inside Ukraine. Troops would be doing to other nearby countries. The UK and USA are drawing down embassy staff…